COMP <GO>
RL vs TMO // ALTMAN Z-SCORE & DEBT/EQUITY
Ralph Lauren Corporation (NYSE) VS. Thermo Fisher Scientific Inc (NYSE) • 15-METRIC TALLY: RL 11
— TMO 4
▲ ALTMAN Z-SCORE & DEBT/EQUITY LEADER: RL
LAST: $392.87 (-1.91%) • MKT CAP: $23.86B
balance-sheet
6.25
LAST: $697.00 (-1.72%) • MKT CAP: $262.22B
balance-sheet
4.50
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (RL VS. TMO)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | RL | TMO | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 69.90% | 41.00% | +28.90 | RL | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | 44.50% | 9.30% | +35.20 | RL | /roic <GO> |
| EV/EBITDA & P/E Valuation | 15.5x | 30.4x | -14.90 | RL | /valuation <GO> |
| Free Cash Flow Yield | 3.31% | 2.40% | +0.91 | RL | /fcf-yield <GO> |
| Operating Margin | 14.50% | 17.40% | -2.90 | TMO | /operating-margins <GO> |
| Net Profit Margin | 11.60% | 15.10% | -3.50 | TMO | /net-margins <GO> |
| Revenue Growth (YoY) | 14.60% | 3.90% | +10.70 | RL | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.91% | 0.24% | +0.67 | RL | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity ACTIVE | 6.25 | 4.50 | +1.75 | RL | /balance-sheet <GO> |
| Piotroski F-Score Quality | 9/9 | 8/9 | +1.00 | RL | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | 6.60% | 6.70% | -0.10 | RL | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 62.3 | 59.1 | +3.14 | RL | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | 0.90 | 0.94 | -0.04 | TMO | /macro-sensitivity <GO> |
| Forward P/E Multiple | 21.3x | 36.3x | -15.00 | RL | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $23.86B | $262.22B | -$238.35B | TMO | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | RL REV | TMO REV | RL GROSS % | TMO GROSS % | RL FCF | TMO FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $8.11B | $44.56B | 69.9% | 44.0% | $789.0M | $6.29B |
| FY 2024 | $7.08B | $42.88B | 68.6% | 44.0% | $916.5M | $7.27B |
| FY 2023 | $6.63B | $42.86B | 44.0% | 44.0% | $771.3M | $6.48B |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
RL // BETA 0.90
TMO // BETA 0.94